Technical Analysis for PBYI - Puma Biotechnology Inc

Grade Last Price % Change Price Change
grade F 15.45 0.98% 0.15
PBYI closed up 0.98 percent on Friday, May 24, 2019, on 73 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Down Down
See historical PBYI trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.98%
Narrow Range Bar Range Contraction 0.98%
NR7 Range Contraction 0.98%
New 52 Week Low Weakness 0.98%
Wide Bands Range Expansion 0.98%
Oversold Stochastic Weakness 0.98%

Older signals for PBYI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Chemistry Cancer Chemical Compounds Organic Compounds Non Small Cell Lung Cancer Chloroarenes Pyridines Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Protein Kinase Inhibitor Aromatic Amines Her2/Neu Advanced Breast Cancer Nitriles Treatment Of Advanced Breast Cancer Treatment Of Various Forms Of Cancer
Is PBYI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 65.45
52 Week Low 15.075
Average Volume 1,054,528
200-Day Moving Average 32.7043
50-Day Moving Average 31.0718
20-Day Moving Average 23.2265
10-Day Moving Average 16.256
Average True Range 1.6234
ADX 58.06
+DI 5.4042
-DI 45.5238
Chandelier Exit (Long, 3 ATRs ) 29.3898
Chandelier Exit (Short, 3 ATRs ) 19.9452
Upper Bollinger Band 38.3293
Lower Bollinger Band 8.1237
Percent B (%b) 0.24
BandWidth 130.048006
MACD Line -4.9085
MACD Signal Line -4.3843
MACD Histogram -0.5241
Fundamentals Value
Market Cap 574.83 Million
Num Shares 37.2 Million
EPS -8.14
Price-to-Earnings (P/E) Ratio -1.90
Price-to-Sales 0.00
Price-to-Book 37.58
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.47
Resistance 3 (R3) 16.50 16.19 16.30
Resistance 2 (R2) 16.19 15.93 16.18 16.24
Resistance 1 (R1) 15.82 15.77 16.01 15.79 16.19
Pivot Point 15.51 15.51 15.60 15.50 15.51
Support 1 (S1) 15.14 15.25 15.33 15.11 14.71
Support 2 (S2) 14.83 15.09 14.82 14.66
Support 3 (S3) 14.46 14.83 14.60
Support 4 (S4) 14.43